Business
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO and MGTI
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO and MGTI.
About this update from Mgt Capital Investments, Inc.
[{"type":"text","content":"\nNEW YORK, Oct. 10, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.\n Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) Class Period: December 14, 2017 to August 7, 2018 Lead Plaintiff Deadline: October 24, 2018 According to the complaint, Ampio Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times. Get additional information about the AMPE lawsuit: http://www.kleinstocklaw.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3 Nevro Corp. (NYSE: NVRO) Class Period: January 8, 2018 to July 12, 2018 Lead Plaintiff Deadline: October 22, 2018 The complaint alleges that during the class period Nevro Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza I and Senza II systems; (2) as a result, Nevro's Senza I and Senza II systems were not \"novel\" or \"proprietary;\" (3) these practices caused Nevro to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro's U.S. sales growth was not sustainable; and (5) consequently, defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. Get additional information about the NVRO lawsuit: http://www.kleinstocklaw.com/pslra-1/nevro-corp-loss-form?wire=3 MGT Capital Investments Inc. (OTCMKTS: MGTI) Class Period: October 9, 2015 to September 7, 2018 Lead Plaintiff Deadline: November 27, 2018 The complaint alleges MGT Capital Investments Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a ...